This case was initially received via regulatory authority (b)(4) on (b)(6) 2017.This spontaneous case was reported by a consumer and describes the occurrence of abdominal pain lower ("low abdominal pain") and depression ("severe depression") in a (b)(6) -year-old female patient who had essure (batch no.700547) inserted.The occurrence of additional non-serious events is detailed below.On (b)(6) 2010, the patient had essure inserted.On the same day, the patient experienced abdominal pain lower (seriousness criterion medically significant), depression (seriousness criterion disability), hot flush ("enormous hot flushes"), arthralgia ("joint pain"), myalgia ("muscle pain"), eczema ("eczema"), fatigue ("enormous and persistent fatigue"), visual impairment ("important vision decrease"), tinnitus ("tinnitus"), tachycardia paroxysmal ("bout of tachycardia"), dyspnoea exertional ("breathless at the slightest effort") and hyperhidrosis ("excessive sweats in whole body leading to isolation").On an unknown date, the patient experienced disturbance in attention ("lack of concentration") and menorrhagia ("more abundant menstruations").The patient was treated with antidepressants.At the time of the report, the abdominal pain lower, depression, hot flush, arthralgia, myalgia, eczema, fatigue, visual impairment, tinnitus, tachycardia paroxysmal, dyspnoea exertional, hyperhidrosis, disturbance in attention and menorrhagia outcome was unknown.The reporter provided no causality assessment for abdominal pain lower, arthralgia, depression, disturbance in attention, dyspnoea exertional, eczema, fatigue, hot flush, hyperhidrosis, menorrhagia, myalgia, tachycardia paroxysmal, tinnitus and visual impairment with essure.The reporter commented: impossibility to work full time due to fatigue and antidepressive treatment (disability class 1).Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be (b)(6) kgs.Quality-safety evaluation of ptc: unable to confirm complaint.Most recent follow-up information incorporated above includes: on 9-oct-2017: quality-safety evaluation of ptc.The list of similar cases contains essure reports received by bayer and older cases received by conceptus with similar events coded in meddra.In this particular case a search in the database was performed on 10-oct-2017 for the following meddra preferred term: abdominal pain lower.The analysis in the global safety database revealed 577 cases.Bayer is closely monitoring the benefit-risk profile of essure.A recent cumulative review of all available data on essure has not yielded any new safety signal with regard to this meddra pt.Further company follow-up with the consumer or regulatory authority is not possible.Incident: at the time of reporting, there is no evidence that a device-related defect or malfunction caused a death or serious injury.If additional information becomes available it will be provided on a supplemental report.
|